We developed a gas chromatography-isotope dilution highresolution mass spectrometry (GC-ID-HRMS) method for quantifying isomers of benzo[a]pyrene (BaP) tetrol metabolites resulting from hydrolysis of benzo[a]pyrene-diol-epoxide hemoglobin (BaPDE-Hb) adducts. Acid hydrolysis of BPDE-Hb adducts extracted from human blood samples yielded isomers of benzo[a]pyrene-tetrahydrotetrols, (±)-BaP-r-7,t-8,t-9,c-10-tetrol (BPTI-1), (±)-BaP-r-7,t-8,t-9,t-10-tetrol (BPTI-2), (±)-BaP-r-7,t-8,c-9,t-10-tetrol (BPTII-1), and (±)-BaP-r-7,t-8,c-9,c-10-tetrol (BPTII-2). The isomeric BaP tetrols were isolated from the matrix by liquid-liquid extraction, and then further purified by solid-phase extraction. Following silylation with N-methyl-N-(trimethylsilyl)-trifluoroacetamide, the analytes were measured by GC-HRMS, using electron ionization. We have found detectable concentrations in the low fmol range for BPTII-1 and BPTI-1 in all donors tested. The mean BaP adduct levels for smoking donors (n = 9) were 0.022 fmol/mg hemoglobin for BPTII-1 and 0.070 fmol/mg hemoglobin for BPTI-1. The mean BaP adduct levels with hemoglobin for non smoking donors (n = 6) was 0.021 fmol/mg hemoglobin for BPTII-1 and 0.105 fmol/mg hemoglobin for BPTI-1.
Introduction
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous in the environment. They are produced from incomplete combustion of natural or synthetic organic materials, industrial production of petroleum products, combustion of refuse, tobacco smoke, and automobile exhaust. Generally occurring as complex mixtures, they are found throughout the environment in air, water, and soil. The most important sources of human exposure to PAHs are via food and water consumption, air pollution and tobacco smoke. Environmental and occupational exposure to PAHs represents a major external factor in the etiology of a number of cancers, including those of the liver, lung, colon, and bladder (1) (2) (3) .
Benzo [a] pyrene (BaP), the first PAH recognized to have carcinogenic activity, has been widely used as a biomarker for PAH exposure (4, 5) . A direct link between BaP exposure and site-specific hotspot mutations in the p53 tumor suppressor gene has been demonstrated; therefore, BaP has been widely utilized as a model for carcinogenic and mutagenic studies. Molecular toxicity studies of PAH exposure have historically been expressed in terms of animal models (6) . However, because of the significant differences in species response, translating such data into human health risk estimates is difficult. Because the biologically effective dose cannot be measured directly, it is possible to estimate human PAH exposure through measurements of biological markers.
Various biomarkers have been investigated as potential candidates to assess human PAH exposure. These include metabolites in urine (7) (8) (9) (10) , chromosomal aberrations (11, 12) , biological endpoints such as enzyme activities (13, 14) , covalent PAH adducts with DNA (15) (16) (17) (18) (19) (20) (21) , and covalent protein adducts (22) (23) (24) (25) (26) (27) (28) (29) . GC-MS has been utilized to measure hydroxy-PAH metabolites in urine (9, 10) . However, PAHs have a relatively short half-life; therefore, urinary metabolites reflect only recent exposures that have occurred in the previous 48-72 h, rather than chronic low-dose exposures. HPLC-MS and GC-MS have been utilized for measurement of DNA-PAH adducts in human tissue and autopic samples (30) (31) (32) (33) . Covalent PAH adducts with DNA and with blood proteins are specific to a given PAH. However, limited success has been achieved with DNA adducts because DNA is rapidly repaired (34) (35) (36) ; the issue is further complicated by interindividual variation. PAH adducts with proteins, such as hemoglobin (Hb), persist and accumulate over the lifetime of the protein. Protein adducts potentially generate an extended window (hemoglobin lifespan is 120 days) for analytical measurements because they integrate the biological effective dose over the lifetime of the protein (37) (38) (39) .
The carcinogenic potency of PAHs is dependent upon the metabolic biotransformation to electrophilic intermediates capable of forming covalent adducts with the nucleophilic centers of DNA and blood proteins. The reaction of BaP with hemoglobin (Hb) has been well characterized (40) (41) (42) . BaP has been shown to form stable ester adducts with Hb via alkylation of the carboxylate groups in the protein. Disruption of the tertiary structure of the protein releases BaP tetrol metabolites. The released tetrol metabolites are used as a quantitative measure of exposure to BaP.
Numerous theories regarding the mechanism of BaP activation have been proposed (5, 39, 43) . The currently accepted mechanism involves metabolic activation by cytochrome P450 monooxygenase and epoxide hydrolases, resulting in the formation of two carcinogenic vicinal diolepoxides, (+)-anti and (-)-syn 7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo(a)-pyrene (anti-and syn-BaPDE). The (+)-anti-BaPDE is the predominate isomer formed; it is the most potent and carcinogenic diolepoxide (44) . The BaPDEs can form covalent adducts with hemoglobin by binding to carboxylate groups in the protein (40) . Under hydrolytic conditions, the tertiary structure of the protein is disrupted, generating isomeric 7,8,9,10-tetrahydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene (BaP tetrols).
The stereochemical origin of the diolepoxide involved in adduct formation has been well characterized (45) . Proteins adducted by the (-)-syn-diolepoxide result in release of BaP tetrols, BPTII-1 and BPTII-2, following hydrolysis. BPTI-1 and BPTI-2 both arise from the mutagenic and carcinogenic diolepoxide, (+)-anti-BaPDE (Figure 1 ). Quantification of BaP tetrols released after protein adduct hydrolysis reflects the amount of BaP exposure; and it thereby can provide an accurate, accessible, and cost-effective foundation for a more realistic risk estimate of PAH exposure in humans.
We have developed the first gas chromatography-isotope dilution high-resolution mass spectrometry (GC-ID-HRMS) method for measuring isomeric BaP tetrols resulting from hydrolysis of BPDE-hemoglobin adducts. Using 13 C 6 -labeled internal standards for each of the four BaP (±)-7,8,9,10-tetrahydrotetrol isomers, we applied mass, retention time, and fragmentation parameters to the quantitative measurement of individual derivatized BaP tetrol isomers. We have observed the occurrence and distribution of isomeric BaP tetrols derived from acid hydrolysis of BPDE-hemoglobin adducts extracted from the blood of a cohort of smoking and non-smoking human subjects.
Experimental

Materials and methods
The native benzo[a]pyrene tetrol isomer standards, (±)-BaPr-7,t-8,t-9,c-10-tetrol (BPTI-1), (±)-BaP-r-7,t-8,t-9,t-10-tetrol (BPTI-2), (±)-BaP-r-7,t-8,c-9,t-10-tetrol (BPTII-1) and (±)-BaPr-7,t-8,c-9,c-10-tetrol (BPTII-2), were obtained from the NCI Chemical Carcinogen Repository, Midwest Research Institute (Kansas City, MO). The 13 C 6 -BaP tetrol isomers were customsynthesized and purchased from Cambridge Isotopes Laboratories (Andover, MA). Solid-phase extraction (SPE) cartridges (Sep-Pak 1 g C18) were obtained from Waters (Milford, MA). The derivatizing agents, N-methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA) and tetrahydrofuran (THF), were purchased from Sigma Chemicals (St Louis, MO). Human hemoglobin and ethyl acetate (EtOAC) (HPLC grade) were purchased from Sigma Aldrich. The 2,2',3,4,4',5'-hexachlorobiphenyl-13 C 6 was purchased from Cambridge Isotopes Laboratories (Andover, MA). All chemicals and solvents were used without further purification.
Native standards
Individual stock solutions of BPTII-1, BPTI-1, BPTI-2, and BPTII-2 were prepared in amber glass vials by dissolving 0.5 mg of each standard into 1 mL of 2:1 solution of THF/DMSO and then mixing well. Air in the vials was displaced with argon. The stock standards were sealed and stored at -70°C until used. 
Internal standards
Internal standard stock solutions were prepared in amber glass vials by dissolving 0.5 mg of each 13 C 6 -isotopically labeled standard into 4 mL of a 2:1 solution of THF/DMSO and mixing well. An internal standard spiking solution was prepared by diluting the stock solution with THF to a concentration of 200 pg/µL. The standard mixture was divided into smaller aliquots. Air in the vials was displaced with argon. The samples were sealed and stored at -70°C until used.
Recovery standard
The recovery standard, 2,2',3,4,4',5'-hexachlorobiphenyl-13 C 6 ( 13 C 6 -PCB-138, 40 ng/µL), was purchased neat and diluted to a working concentration of 350 pg/µL and a final volume of 4 mL. The recovery standard was divided into smaller aliquots, sealed, and stored in the refrigerator until used.
Calibration curve standards
The calibration curve standards were prepared by serial dilution of the stock native standards with THF. From the stock native standards, 12 working standard sets (0.01, 0.025, 0.05, 0.10, 0.25, 0.5, 1, 5, 10, 25, 50, and 100 pg/µL) were prepared for native standards BPTII-1 and BPTI-1 by serial dilution with THF. A set of 12 working standard sets (0.05, 0.10, 0.25, 0.5, 1, 5, 10, 25, 50, 100, 200, and 400 pg/µL) was prepared for native standard BPTI-2 and BPTII-2. The concentrations of the native standards were varied as described. The labeled internal standard concentration was kept constant. The internal standard spiking solution was spiked into all calibration standards, for a final concentration of 10 pg/µL. The recovery standard 13 C 6 -PCB-138 was spiked into all calibration standards at a concentration of 6 pg/µL. The calibration standards were run before the unknown samples.
Human subjects
The method was used to measure BaP tetrol levels in the blood of volunteer donors. The IRB protocol was reviewed and approved by the CDC human subjects review board for the protection of human subjects prior to sample collection. A questionnaire was administered to each volunteer to record sex, age, race/ethnicity, and smoking history. Informed consent was also obtained from each donor. Blood, 10 mL, was collected from each donor into vacutainer tubes containing EDTA as an anticoagulant.
Isolation of hemoglobin from red blood cells
The blood, 10 mL, was transferred to centrifuge tubes and centrifuged at 4000 rpm at 4°C for 5 min. After centrifugation, the plasma was removed. The red blood cells were washed twice with 5 mL of 0.9% (w/v) sodium chloride solution and resuspended in 5 mL of phosphate buffered saline (PBS, pH 7.4). The packed red blood cells were lysed with two volumes of lysis buffer and centrifuged to remove ghost cell membranes. After centrifugation, the supernatant was collected and the hemoglobin was precipitated by addition of a cold solution of 0.015% HCl in acetone (25 mL) while stirring. The precipitated hemoglobin was collected by centrifugation and dried under a constant stream of nitrogen gas (37°C; 10 psi). After drying, the protein was weighed and divided into 200 mg samples and dissolved in 4 mL of 18 mega-ohm water.
Hydrolysis and purification of BaPDE-Hb adducts
The hemoglobin samples, 200 mg/4 mL of 8 mega-ohm water, were spiked with 40 µL of 9N HCl and incubated for 3 h at 90°C. After hydrolysis, the samples were allowed to cool to room temperature. The samples were spiked with 4.3 µL of the 13 C 6 -labeled internal standard spiking solution (200 ng/mL), for a final concentration of 10 pg/µL. The hydrolysates were extracted twice with 12 mL of ethyl acetate. After each ethyl acetate addition, the samples were vortex mixed, and the aqueous and organic layers were allowed to separate. The organic layers were combined and evaporated to dryness on a turbovap under a steady stream of nitrogen gas at 15 psi and 52°C. The sample extracts were reconstituted in 5 mL of 50% aqueous MeOH and further purified by SPE (SepPak C18, 1 g). The SPE cartridges were conditioned with 5 mL of methanol and equilibrated with 5 mL of water. The reconstituted samples were slowly added to the column and allowed to incubate on the column for 5 min at room temperature. The columns were washed with 5 mL of water and 5 mL of 50% MeOH. The columns were dried under vacuum for 5 min and subsequently eluted with 5 mL of 50:50 acetonitrile/methanol. The SPE extracts were concentrated to dryness on a turbovap under a steady stream of nitrogen gas (55°C, 15 psi), reconstituted in 24.3 µL of anhydrous THF, and added to amber derivatization vials. All samples were run in triplicate.
Derivatization of BaP tetrols
The BaP tetrols were converted to their trimethylsilyl (TMS) derivatives by addition of 30 µL of MSTFA and 15 µL of 10% triethylamine (TEA) in hexane. The samples were spiked with 16 µL of the 13 C 6 -PCB-138 recovery standard stock solution (350 pg/µL), for a final concentration of 6 pg/µL of recovery standard. The samples were incubated for 90 min at 60°C.
Reagent, method, and instrument blanks
The reagent blanks consisted of 4 mL of 18 mega-ohm water, ethyl acetate, and THF. The water blank contained the same water used in the sample preparation procedures and in the preparation of solvents for SPE. The water blanks were treated in the same manner as the unknown samples. The ethyl acetate and THF reagent blanks were analyzed directly by MS. The reagent blanks ensured that contamination did not occur during any step in the process. Hemoglobin purchased from Sigma was used as method blanks. Hemoglobin purchased from Sigma (200-mg aliquots) was previously subjected to our clean-up method and analyzed by GC-HRMS. A total of 20 × 200-mg aliquots were analyzed. We did not find detectable levels of BaP tetrol isomers in any of the Sigma Hb samples analyzed. During unknown sample analysis, the hemoglobin blank samples were treated in the same manner as the unknown samples. Only data generated in runs in which BaP tetrol levels in the hemoglobin blank samples were non-detectable were considered valid. THF blanks (2 µL) were run on the HRMS after each unknown or calibration standard to assess and validate that there was no sample carry-over.
Quality control
Hemoglobin, purchased from Sigma, was aliquoted into amber vials, each containing 200 mg of protein. The protein samples were dissolved in 4 mL of water. The samples were mixed by vortex and incubated for 3 h at 90°C. After incubation, the native BaP tetrol standards, BPTII-1, BPTI-1, BPTI-2 and BPTII-2, were spiked into the appropriately labeled vials to generate the following concentrations: low QC standard concentration (5 pg/µL of BPTII-1 and BPTI-1 and 10 pg/µL of BPTI-2 and BPTII-2); and high QC standard concentration (10 pg/µL of BPTII-1 and BPTI-1 and 20 pg/µL of BPTI-2 and BPTII-2). All samples were spiked with 4.3 µL of the 13 C 6 labeled standard spiking solution (200 ng/mL) and vortex mixed. The QC samples were extracted with ethyl acetate and further purified by SPE as previously described. The SPE extracts were reconstituted in 24.3 µL of anhydrous THF and added to amber derivatization vials and derivatized with MSTFA as previously described. After derivatization, the sample extracts (2 µL) were analyzed by GC-HRMS (Table I) .
Instrumental analysis
Two microliters of the TMS-derivatized tetrol solutions were analyzed by use of splitless injection GC-HRMS. The analysis was performed on a Thermo-Finnigan MAT-95XL HRMS (ThermoFinnigan, Bremen, Germany) equipped with an electron impact ionization source and interfaced to an Agilent Technologies 6890 GC (Agilent Technologies, Palo Alto, CA) with a CTC A200S autosampler. The GC injector port temperature was set at 280°C and operated in splitless mode. The initial pressure was set at 8 psi. A constant flow rate of 1 mL/min of helium was maintained throughout the GC run. A J&W DB-5MS 25-m fused silica capillary column (0.25-mm i.d., 0.25-micron film thickness) was used for analyte separation. The initial oven temperature was held at 140°C for 2 min, increased to 310°C at 20°C/min for 8 min, and then held at 310°C for 6 min, for a total run time of 16 min. The MS was operated in single ion monitoring (SIM) mode. The initial accelerating voltage was 4000 eV, and the resolution was 10,000 (10% valley). Perfluorophenanthrene (FC-5311) was used to calibrate and tune the instrument. FC-5311 ions, m/z 366.9792 and m/z 404.9760, were used as the lock and calibration masses. The instrument was calibrated to 10,000 resolution and maximum sensitivity. The remaining MS conditions were as follows: ion source, 270°C; emission current, 0.5 mA; and electron energy, 40 eV.
Quantification
Calibration curves were constructed with 12 different concentrations for the native BaP tetrol analytes BPTII-1, BPTI-1 and BPTI-2 and BPTII-2. The concentration was plotted against the analyte response factors. Response factors were calculated as the area of the native tetrol ion divided by the area of the isotopically labeled ion. Six repeat measurements were performed at each concentration level. Calibration concentrations encompassed the entire liner range of the analysis. The lowest standard concentration for each native analyte was below the LOD. The standard deviation at zero concentration (s 0 or y intercept) was determined by a linear regression plot of the standard deviation (in units of concentration) versus the concentration of the lowest calibration standards. From these data, the analytical limit of detection (LOD or 3s 0 ) for the method was calculated for each analyte.
Results and Discussion
The native BaP tetrol standards and the 13 C 6 -labeled standards were first characterized by GC-EI-HRMS. Full scan analysis revealed a single product peak for each native and labeled BaP isomer. Single ion monitoring (SIM) was applied for the detection of the native BaP tetrol isomer standards and the 13 C 6 -labeled standards, using the most abundant fragment ions m/z 404.1628 and m/z 410.1829 (relative intensity 100) for quantification of the native tetrols and the 13 C 6 -labeled tetrol standards, respectively. The retention times observed for native BaP tetrol isomers were 12.39, 12.66, 13.20, and 13.68 min for BPTII-1, BPTI-1, BPTI-2, and BPTII-2, respectively ( Figure 2) . Calibration curves were constructed for each BaP tetrol isomer. Because of the difference in response factor for each analyte, the native standard concentration ranged from 0.01 to 100 pg/µL for BPTII-1 and BPTI-1. The native standard concentration ranged from 0.05 to 400 pg/µL for BPTI-2 and BPTII-2. The 13 C 6 -labeled internal standard concentration was kept constant at 10 pg/µL. Regression coefficients of the calibration curves were r 2 = 0.97, 0.98, 0.98, 0.98 for BPTII-1, BPTI-1, BPTI-2, and BPTII-2 respectively. The analytical LODs (3s 0 ) for BPTII-1, BPTI-1, BPTI-2, and BPTII-2 were 0.02, 0.04, 0.75, and 0.13 pg/µL, respectively. We measured BaP tetrol levels resulting from mild acid hydrolysis of benzo[a]pyrene-diol-epoxide (BPDE) hemoglobin adducts (BPDE-Hb) extracted from the blood of a cohort of smoking and non-smoking volunteer donors. A total of 15 donors were examined (9 smokers and 6 nonsmokers). Data on race, sex, age of each donor were collected via questionnaire. Volunteer donors self identified as smokers or non-smokers. For nonsmoking donors (Table II) , the mean adduct levels for BPTII-1 ranged from 0.015 to 0.04 fmol/mg Hb, with a mean of 0.021 fmol/mg Hb. The mean adduct levels for BPTI-1 ranged from 0.024 to 0.355 fmol/mg Hb, with a mean of 0.105 fmol/mg Hb. For smoking donors (Table III) , the levels for BPTII-1 ranged from 0.012 to 0.046 fmol/mg Hb, with a mean of 0.022 fmol/mg Hb. The levels for BPTI-1 ranged from 0.027 to 0.157 fmol/mg Hb, with a mean of 0.070 fmol/mg Hb. The recovery standard 13 C 6 -PCB-138 was used to calculate the recovery of the 13 C 6 -labeled internal standards. The mean recoveries for the 13 C 6 -labeled internal standards were 102% (± 20.1) for 13 C 6 -BPTII-1 and 111% (± 22.1) for 13 C 6 -BPTI-1.
In some donor samples, there were peaks at the appropriate retention time for BPTI-2 and BPTII-2 (see, for example, Figure 3) . We did not quantify these peaks because we were not able to get reasonable % recoveries for the C-13 labeled internal standards for these two isomers. In cases where peaks were detected for these isomers, the % recoveries of the C-13 labeled internal standards were extremely high, most probably due to the near co-elution of matrix interferences near the retention times of these isomers. We are continuing to modify the method to be able to report valid quantitative levels for these two isomers in samples where they appear.
Accurate measurement of low level analytes depends on the use of good internal standards, since large amounts of endogenous components are also present in the sample matrix. A previous GC-lowresolution MS method used 14 CBPTs as internal standards for quantification of benzo[a]pyrene hemoglobin adducts (46) . However, only two mass units differ between the analytes of interest ( 12 CBPTs ) and the internal standard, preventing accurate measurement of low level analytes. Pastorelli and coworkers utilized a deuterated BaP tetrol (BPT-d 12 ) as an internal standard to quantify BaP adducts in newspaper vendors in Milan, Italy (27) . However, hydrogen deuterium exchange is common, and results may be inconsistent. We have developed a sensitive and accurate method for measurement of BaP tetrol isomers in blood by using isotope dilution high resolution mass spectrometry measurements of BaPDE-hemoglobin adducts and employing 13 C 6 -isotopically labeled BaP tetrol isomer standards.
Our method combines liquid-liquid extraction (LLE) and SPE techniques for isolation and purification of BaP tetrols resulting from acid-hydrolyzed BaPDE-hemoglobin. Acid hydrolysis of hemoglobin was used instead of lengthy enzymatic digestion procedures, which usually take 12-48 h. Ethyl acetate was the more suitable solvent to use for extraction of BaP tetrols from the hemolysates. Emulsions were recurrent when isopropyl ether or chloroform was used as an extraction solvent. The combined LLE/SPE clean-up approach yielded more reproducible results than SPE alone. When hemolysates were directly subjected to SPE, problems with clogging of the cartridges were frequent, yielding results that were not reproducible. Also, the resulting extracts needed additional clean-up before GC-MS analysis.
Comparisons of BaP isomer tetrol levels measured in our study with levels from previous investigators are given in Table IV . The results for a given matrix are comparable, despite extensive variability in sample preparation techniques, internal standards, analytical equipment, and exposure status. Although several authors alluded to individual BaP tetrol isomers in their methods, the published data appear to represent total BaP tetrols (27, 47, 48) . The sum of the mean adduct levels for each BaP tetrol isomer for all donors determined in our study was 0.22 fmole/mg Hb. These results are comparable to results reported by other investigators. Pastorelli et al. (27) and other investigators (48) have reported negligible differences in levels for smokers and non-smokers. Buckley et al. (7) and Phillips (49) have reported the highest non-occupational PAH exposures from diet. Considering interindividual variability in metabolism and the small donor population analyzed in this report, these mean levels are consistent with reported values.
Conclusions
We have developed a sensitive and accurate method for measurement of benzo[a]pyrene tetrol isomers in blood by using ID-HRMS measurements of BaPDE-hemoglobin adducts and employing 13 C 6 -isotopically labeled BaP tetrol isomer standards. We have found detectable concentrations of BPTII-1 and BPTI-1 in all donors tested. The donor samples were used for method development purposes. We did not design a study to look at BaP adduct levels in smokers versus nonsmokers. However, but we did not observe any discernible differences in isomer adduct levels in smokers and nonsmokers for BaP tetrols isomers BPTII-1 and BPT1-1 (Tables II and III) . BPTI-1 levels were higher than BPTII-1 levels in both smokers and nonsmokers. For smokers, the mean BaPDE hemoglobin adduct levels were 0.022 and 0.070 fmol/mg hemoglobin for BPTII-1 and BPTI-1, respectively. For nonsmokers, the mean BaPDE hemoglobin adduct levels were 0.021 and 0.105 fmol/mg hemoglobin for BPTII-1 and BPTI-1, respectively. BPTI-1 hemoglobin adduct levels were 3.2-and 5-fold higher than BPTII-1 in smokers and nonsmokers, respectively. BPTI-1 is formed from hydrolysis of the anti-BaPDE, and the results we obtained are consistent with reports that the (+)-anti-BaPDE is the predominate diolepoxide formed in humans (44) . The variability from person to person can be attributed to interindividual variations in metabolism and exposures such as diet, in-home exposures, the working environment, and commuting exposures.
Because the mutagenicity and carcinogenicity profiles of the BaPDE differ (44) , protein adducts biomonitoring methods should be sensitive enough to measure and identify specific BaP tetrol isomers. The analytical detection limits obtained by our method for the BaP tetrol isomers are in the low pg/µL range. Various (17, 29, 47, 48) or measurable levels of BPTI-1 (29) . Using our method, we have identified specific BaP tetrol isomers and have consistently observed analyte peaks above the limit of detection for BPTII-1 and BPTI-1 in smokers and nonsmokers.
